Session 3: Biology of breast cancer II: Tumor heterogeneity and disease segmentation in breast cancer
Chairs: Fraser W. Symmans (USA), Jonas Bergh (Sweden)
- Clinical implications of the intrinsic molecular subtypes (Aleix Prat, Spain)
- Heterogeneity of Triple Negative subtype: Gene expression profile and phenotype (Brian D. Lehmann, USA)
- Molecular segmentation in Luminal breast cancer: How to select the driver pathways (Sherene Loi, Australia)
- Insights in biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications (Nadja Harbeck, Germany)
- Discussion